The comparison of three different molecular imaging methods in localization and grading of insulinoma.
Front Endocrinol (Lausanne) · 2023
Last updated 2026-05-28In a study of 28 people with insulinomas, a type of pancreatic tumor, Exendin-4 PET/CT scans correctly identified all tumors (100% sensitivity), outperforming Ga-DOTATATE PET/CT (75%) and F-FDG PET/CT (57%). Exendin-4 PET/CT was especially better at finding smaller tumors (≤20 mm or ≤15 mm) and higher-grade tumors, though all methods missed a metastatic lymph node in one patient.
AI summary of the abstract below.
| Journal | Front Endocrinol (Lausanne), 2023 |
|---|---|
| Citations | 10 |
| Relative citation ratio | 1.97 |
| NIH percentile | 73 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
AIMS: This cross-sectional study compared the value of molecular imaging (Exendin-4 positron emission tomography/computed tomography [PET/CT], Ga-DOTATATE PET/CT, F- fluorodeoxyglucose [FDG] PET/CT) in insulinoma localization by stratified tumor size and grading, and explored the correlation of the related the maximum standardized uptake value (SUVmax) with insulinoma grading, Ki-67, maximum tumor diameter, and glucose metabolism.
METHODS: In 28 insulinoma patients, the sensitivity of three types of PET/CT for localizing insulinoma was calculated according to tumor size and grade. We compared the SUVmax for different insulinoma grades and analyzed the correlation of SUVmax with Ki-67, maximum tumor diameter, and glucose metabolism indicators.
RESULTS: The study included 12 grade (G) 1 and 16 G2 cases, with maximum tumor diameters ranging from 9 to 40 mm. Without differentiation by size and grade, the sensitivity of Exendin-4 PET/CT to localize insulinoma was 100%, which significantly exceeded that of Ga-DOTATATE PET/CT and F-FDG PET/CT (75% and 57%, respectively). In tumors with a maximum diameter ≤ 20 mm and ≤ 15 mm, the sensitivity of Exendin-4 (both 100%) significantly exceeded that of Ga-DOTATATE PET/CT (74% and 64%, respectively) and F-FDG PET/CT (54% and 50%, respectively). In G1 tumors, the sensitivity of Exendin-4 PET/CT was significantly higher than that of F-FDG PET/CT, but not that of Ga-DOTATATE PET/CT, while in G2 tumors, the sensitivity of Exendin-4 PET/CT was significantly higher than that of both other types. However, all three PET/CT types missed a metastatic lymph node in one patient. The F-FDG PET/CT SUVmax was significantly lower than that of the other PET/CT types and that of Ga-DOTATATE PET/CT was significantly lower in G2 than in G1. Ga-DOTATATE PET/CT SUVmax correlated negatively with Ki-67. A receiver operating characteristic (ROC) curve suggested that Ga-DOTATATE PET/CT SUVmax > 19.9 could predict G1 tumors.
CONCLUSION: Exendin-4 PET/CT was superior to Ga-DOTATATE PET/CT and F-FDG PET/CT for insulinoma localization, particularly small and G2 tumors, but its diagnostic value in small metastatic lymph nodes requires further exploration. Ga-DOTATATE PET/CT SUVmax could be used as an adjunct to pathology, and a value > 19.9 could predict G1 tumors. No PET/CT SUVmax could predict tumor maximum diameter and glucose metabolism.
Verbatim abstract via PubMed 37455905 ↗